Current advances in understanding neuroprotective effect of acteoside in neurodegenerative disease
10.3969/j.issn.1001-1978.2021.07.005
- Author:
Dan-Dan HAO
1
;
Feng-Ning ZHANG
1
;
Chun-Ying BAI
1
;
Chun-Ying SIRIGULENG
1
;
Yun RUI
1
;
Lei ZHANG
2
;
Wei-Hong LANG
3
;
Guan-Hua DU
4
;
Hong-Quan WANG
5
Author Information
1. Dept of Physiology, Medical College, Chifeng University
2. Dept of Neurosurgery, Affiliated Hospital, Chifeng University
3. Dept of Psychological Medicine, Affiliated Hospital, Chifeng University
4. Institute of Materia Medica, CAMS/PUMC
5. Dept of Neurology, Aerospace Center Hospital, Peking University, Aerospace School of Clinical Medicine
- Publication Type:Journal Article
- Keywords:
acteoside;
Alzheimer's disease;
neurodegenerative disease;
neuroprotection;
Parkinson' s disease
- From:
Chinese Pharmacological Bulletin
2021;37(7):906-910
- CountryChina
- Language:Chinese
-
Abstract:
Acteoside is among the most widespread of thedisaccharide caffeoyl esters that are widely distributed in the plant kingdom with diverse biological activities. Recent studies have shown that acteoside has neuroprotective activity in neurodegenerative diseases. This review examines and extrapolates from the recent literature to build support for the use of acteoside in mitigating neuropathy in neurodegenerative disease, including Parkinson ' s disease (PD) and Alzheimer' s disease (AD). We summarize the main pharmacokinetic parameters of acteoside in animals after different administration routes. Meanwhile, we point out both problems and shortcomings, and highlight its future development trend.
